Francisco J. Barrera-López, Servicio de Medicina Interna, Centro Médico Nacional Siglo XXI, Hospital de Especialidades, Instituto Mexicano del Seguro Social (IMSS), Ciudad de México, México
Maura E. Noyola-García, Servicio de Medicina Interna, Centro Médico Nacional Siglo XXI, Hospital de Especialidades, Instituto Mexicano del Seguro Social (IMSS), Ciudad de México, México
Natalia G. Barrera-López, Centro de Investigación Biomédica de Occidente, Centro Médico Nacional de Occidente, IMSS, Guadalajara, Jalisco, México
Alejandra Albarrán-Sánchez, Servicio de Medicina Interna, Centro Médico Nacional Siglo XXI, Hospital de Especialidades, Instituto Mexicano del Seguro Social (IMSS), Ciudad de México, México
Background: Mucormycosis is an infection caused by Mucorales. Management includes surgical treatment and antifungals. Objective: To describe the surgical and medical complications associated with mucormycosis in a third-level hospital. Material and methods: Records of patients with mucormycosis treated between 2019 and 2022 were collected. Results: A total of 25 patients were obtained, 17 (68%) men and 8 (32%) women. Surgical complications occurred on admission in 16% and early in 4% of cases. The most frequent medical complications were soft tissue infection on admission (84%) and late sepsis (52%). Amphotericin B deoxycholate was used in all cases, finding hypokalemia in 20 (80%), hypomagnesemia in 18 (72%), and acute kidney injury in 15 (60%). Conclusions: The most commonly performed surgery was surgical debridement on admission (76%). Surgical complications occurred mainly on admission (16%). The most frequent medical complications were soft tissue infection on admission (84 %) and late sepsis (52 %). Due to the high cost of the liposomal and lipid forms of amphotericin, the use of amphotericin B deoxycholate continues to persist in our setting, which leads to a high degree of renal toxicity and hydroelectrolytic alterations.
Keywords: Mucormycosis. Treatment. Complications.